Key Takeaways
- FMC Corporation has entered into a framework agreement to sell its Newark, Delaware property for gross proceeds of approximately $114 million, with closing expected in Q4 2026.
- FMC intends to lease back the facilities it actively operates under a separate agreement, while retaining ownership of its adjacent Maryland properties.
- Proceeds from the sale will be applied directly to debt reduction rather than reinvestment in new assets.
- The Stine Research Center, FMC's global R&D headquarters, will continue to operate at the site following the transaction with no disruption to research activities.
- The framework agreement remains subject to a due diligence period and closing conditions; there is no guarantee the transaction will proceed as structured.
FMC Agrees to Sell Delaware Property for $114 Million
FMC Corporation (NYSE: FMC) has entered into a framework agreement to sell its property in Newark, Delaware for gross proceeds of approximately $114 million, subject to a due diligence period and customary closing conditions. The transaction is expected to close in the fourth quarter of 2026. Upon completion, FMC intends to lease back the facilities it actively operates at the site under a separate agreement, while retaining full ownership of its adjacent Maryland properties.
The sale is part of FMC's broader effort to optimise its asset base by converting underutilised real estate into capital. Proceeds will be applied directly to debt reduction, with no impact to the operational capabilities the company considers central to its growth strategy.
Stine Research Center Remains Fully Operational
The transaction has been structured to avoid disruption to FMC's research operations. The Stine Research Center, which serves as the company's global R&D headquarters, will continue to operate at the Newark site following the sale. Core research activities, scientific infrastructure, and R&D capabilities remain fully intact.
“The Stine Research Center remains the global headquarters for FMC's R&D organization and will continue to play a central role in advancing our innovation pipeline. This transaction allows us to optimize our physical footprint by reducing underutilized space while preserving and improving the world-class facilities, infrastructure and scientific talent that power our research and long-term growth,” said Seva Rostovtsev, Executive Vice President and Chief Technology Officer at FMC.
FMC Balance Sheet Focus Behind the Asset Sale
FMC has framed the Newark transaction primarily as a balance sheet move rather than an operational restructuring. The company is looking to reduce debt by unlocking capital tied up in real estate it is not fully utilising, while avoiding any compromise to the scientific and commercial investments it is relying on for future growth.
“Unlocking the value of underutilized real estate and applying the proceeds to debt reduction reflects our ongoing commitment to strengthening our balance sheet without compromising the investments and capabilities that will drive FMC's future growth,” said Andrew Sandifer, Executive Vice President and Chief Financial Officer.
FMC noted that the framework agreement remains at a preliminary stage. The leaseback structure and several other operational and economic terms are still to be agreed between the parties. As is customary, terms may be renegotiated during the diligence period, and there is no assurance the agreement will ultimately result in a completed transaction.
5 Comments